Total amount: € 0,00
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
Online ISSN 1827-1839
Boccalon H. *, Causse C. **, Yubero L. **
From the * Service d’Angiologie, CHU Rangueil, Toulouse,
** Laboratoire Pierre Fabre Cardiovasculaire, Pierre Fabre Medicament, Castres, France
Background. The efficacy of Cyclo 3 Fort has previously been demonstrated in placebo-controlled trials on plethysmographic and clinical parameters . Its objective was to demonstrate that after one month of therapy, the efficacy and safety of a single dose of two capsules of Cyclo 3 Fort in the morning were comparable to that of a twice daily dose of Cyclo 3 Fort, one capsule morning and noon.
Methods. This single-center, randomised, double-blind study was conducted on 37 women with chronic lower-limb venous insufficiency, associating clinical or functional signs and abnormal plethysmographic values. Clinical parameters measured were those conventionally used to assess superficial venous insufficiency; the main laboratory parameter evaluated by plethysmography was the index of venous distensibility.
Results. The results data show that in each of the study groups, all of the patients attained a significant improvement in their clinical conditions, confirmed by laboratory tests, following one month of therapy with Cyclo 3 Fort. On the other hand, comparison of results data between the two groups did not objectify any significant difference between the two treatment modalities.
Conclusions. Thus a single dose of two capsules of Cyclo 3 Fort in the morning appears as effective and as well-tolerated as a twice daily dose of one capsule of Cyclo 3 Fort morning and noon.